Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients

@article{Keene2014EffectOC,
  title={Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients},
  author={D. Keene and C. Price and Matthew J Shun-Shin and D. Francis},
  journal={The BMJ},
  year={2014},
  volume={349}
}
  • D. Keene, C. Price, +1 author D. Francis
  • Published 2014
  • Medicine
  • The BMJ
    • Objective To investigate the effects on cardiovascular outcomes of drug interventions that increase high density lipoprotein levels. Design Meta-analysis. Studies reviewed Therapeutic benefit of niacin, fibrates, and cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular events (all cause mortality, coronary heart disease mortality, non-fatal myocardial infarction, and stroke). Results 117 411 patients were randomised in a total of 39 trials. All interventions increased the… CONTINUE READING
    View on BMJ
    bmj.com
    297 Citations
    Highly Influencial Citations
    3
    Background Citations
    68
    Methods Citations
    8
    Results Citations
    17
    297 Citations
    Citation Type

    Citation Type

    Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis
    • 9
    With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes
    • 1
    • PDF
    Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis
    • 14
    Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial)
    • 6
    Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration.
    Role of Niacin in Current Clinical Practice: A Systematic Review.
    • 31
    Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    • 2
    An update on trials of novel lipid-lowering drugs
    • 3
    High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need
    • 4
    • PDF
    Dysfunctional HDLs are Associated with a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk: A Nested-Case Control Study.
    • 6

    References

    SHOWING 1-10 OF 59 REFERENCES
    Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins
    • 718
    • PDF
    Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    • 2,578
    • PDF
    Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
    • 5,742
    • PDF
    Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
    • 196
    • PDF
    Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    • 1,501
    • PDF
    A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events
    • 178
    Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    • 2,914
    Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    • 3,587
    Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.
    • 34
    Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
    • 2,179
    • PDF